Analysts Set Expectations for Structure Therapeutics Inc.'s FY2024 Earnings (NASDAQ:GPCR)

Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Structure Therapeutics in a report issued on Tuesday, April 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will post earnings of ($1.10) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $65.00 price target on the stock. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.96) per share.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04.

Separately, Lifesci Capital reiterated an "outperform" rating on shares of Structure Therapeutics in a report on Tuesday, February 27th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Structure Therapeutics has an average rating of "Buy" and an average target price of $85.71.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR traded down $0.93 during trading on Friday, hitting $39.32. 438,135 shares of the company traded hands, compared to its average volume of 589,204. The business's fifty day moving average is $41.60 and its 200 day moving average is $48.63. Structure Therapeutics has a fifty-two week low of $21.79 and a fifty-two week high of $75.02. The firm has a market capitalization of $1.83 billion and a price-to-earnings ratio of -48.18.

Hedge Funds Weigh In On Structure Therapeutics

Institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP increased its position in shares of Structure Therapeutics by 404.0% during the fourth quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company's stock worth $178,216,000 after acquiring an additional 3,504,747 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of Structure Therapeutics by 835.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 1,799,923 shares of the company's stock worth $90,752,000 after acquiring an additional 1,607,525 shares in the last quarter. Avoro Capital Advisors LLC increased its position in shares of Structure Therapeutics by 133.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company's stock worth $95,107,000 after acquiring an additional 1,333,333 shares in the last quarter. FMR LLC bought a new stake in Structure Therapeutics in the 1st quarter worth about $29,724,000. Finally, Federated Hermes Inc. grew its position in Structure Therapeutics by 104.2% in the 4th quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company's stock worth $92,411,000 after purchasing an additional 1,157,006 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.